Intercept Pharmaceuticals Liabilities 2024

Intercept Pharmaceuticals Aktienanalyse

What does Intercept Pharmaceuticals do?

Intercept Pharmaceuticals Inc is a biotechnology company based in New York City that focuses on the discovery and development of therapeutics for the treatment of chronic liver diseases. The company was founded in 2002 and has since brought a variety of innovative drugs to the market. The business model of Intercept Pharmaceuticals Inc is based on the invention, development, and marketing of drugs that specifically target certain disease conditions. They primarily focus on the development of drugs for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). These two diseases are prevalent worldwide and pose significant health problems in many Western societies. Intercept Pharmaceuticals Inc has already achieved significant success in the treatment of NAFLD and NASH. The various divisions of Intercept Pharmaceuticals Inc can be divided into research, development of new products, sale of existing drugs, and collaboration with partners and other companies. In research, the company strives to develop the most effective and safe medications, utilizing state-of-the-art technologies and research methods. The main products of Intercept Pharmaceuticals Inc are Ocaliva and obeticholic acid. Ocaliva is a medication used to treat primary biliary cholangitis, a disease that causes inadequate movement of bile through the liver and its accumulation in the body. Ocaliva helps improve bile production and alleviate the symptoms of this disease. Obeticholic acid is a new approach to the treatment of NASH and is currently being tested in clinical trials. Intercept Pharmaceuticals Inc works closely with other companies and organizations to ensure the most effective therapy for patients worldwide. Interaction with industry colleagues, scientific institutions, and experts in the field of medical research allows for faster development of new products that benefit patients. Overall, Intercept Pharmaceuticals Inc has achieved an impressive track record in recent years. The company has established a strong position in the field of liver diseases by advancing research and development in innovative ways. The focus on NAFLD and NASH allows Intercept Pharmaceuticals Inc to play a leading role in this market segment and provide patients with effective medications for their conditions. In summary, Intercept Pharmaceuticals Inc is a company dedicated to the development and marketing of products for the treatment of liver diseases. Through the use of innovative technologies and close collaboration with other companies and organizations, Intercept Pharmaceuticals Inc has already achieved significant success in the development of new medications. The company has established a strong position in this market segment and aims to develop further innovative products to combat liver diseases in the future. Intercept Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Intercept Pharmaceuticals's Liabilities

Intercept Pharmaceuticals's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Intercept Pharmaceuticals's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Intercept Pharmaceuticals's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Intercept Pharmaceuticals's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Intercept Pharmaceuticals’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Intercept Pharmaceuticals stock

What is the level of liabilities of Intercept Pharmaceuticals this year?

Intercept Pharmaceuticals has a debt balance of 460.63 M USD this year.

What were the liabilities of Intercept Pharmaceuticals compared to the previous year?

The liabilities of Intercept Pharmaceuticals have increased by -35.21% dropped compared to the previous year.

What are the consequences of high debt for investors of Intercept Pharmaceuticals?

High liabilities can pose a risk for investors of Intercept Pharmaceuticals, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Intercept Pharmaceuticals?

Low liabilities mean that Intercept Pharmaceuticals has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Intercept Pharmaceuticals affect the company?

An increase in liabilities of Intercept Pharmaceuticals can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Intercept Pharmaceuticals affect the company?

A decrease in the liabilities of Intercept Pharmaceuticals can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Intercept Pharmaceuticals?

Some factors that can influence the liabilities of Intercept Pharmaceuticals include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Intercept Pharmaceuticals so important for investors?

The liabilities of Intercept Pharmaceuticals are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Intercept Pharmaceuticals take to modify the liabilities?

To change its liabilities, Intercept Pharmaceuticals can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Intercept Pharmaceuticals pay?

Over the past 12 months, Intercept Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Intercept Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Intercept Pharmaceuticals?

The current dividend yield of Intercept Pharmaceuticals is .

When does Intercept Pharmaceuticals pay dividends?

Intercept Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Intercept Pharmaceuticals?

Intercept Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Intercept Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Intercept Pharmaceuticals located?

Intercept Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Intercept Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Intercept Pharmaceuticals from 10/10/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/10/2024.

When did Intercept Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/10/2024.

What was the dividend of Intercept Pharmaceuticals in the year 2023?

In the year 2023, Intercept Pharmaceuticals distributed 0 USD as dividends.

In which currency does Intercept Pharmaceuticals pay out the dividend?

The dividends of Intercept Pharmaceuticals are distributed in USD.